Pasar al contenido principal

IMPACTO DE LA HETEROGENEIDAD CELULAR, GENETICA Y EPIGENETICA EN LA PROGRESION Y EL TRATAMIENTO DE LOS TUMORES DEL SISTEMA NERVIOSO PERIFERICO ASOCIADOS A LA NEUROFIBROMATOSIS TIPO 1

PI20/00228

•
Nombre agencia financiadora Instituto de Salud Carlos III
Acrónimo agencia financiadora ISCIII
Programa Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de Investigación en Salud
Año convocatoria 2020
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION INSTITUTO INV GERMANS TRIAS I PUJOL
Centro realización INSTITUTO DE INVESTIGACION GERMANS TRIAS I PUJOL (IGTP)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Expanding a precision medicine platform for malignant peripheral nerve sheath tumors, New patient-derived orthotopic xenografts, cell lines and tumor entities

  • Creus-Bachiller, Edgar
  • Fernández-Rodríguez, Juana
  • Magallon-Lorenz, Miriam|||0000-0003-2741-4572
  • Ortega-Bertran, Sara
  • Navas-Rutete, Susana
  • Romagosa Perez Portabella, Maria Cleofe|||0000-0002-9478-7320
  • Silva, Tulio M.
  • Pané, Maria|||0000-0001-6107-2006
  • Estival, Anna|||0000-0002-2788-9159
  • Perez Sidelnikova, Diana
  • Morell, Mireia
  • Mazuelas, Helena
  • Carrió, Meritxell|||0000-0002-1258-6593
  • Lausová, Tereza
  • Reuss, Diana
  • Gel, Bernat|||0000-0001-8878-349X
  • Villanueva, Alejandro|||0000-0001-5164-0006
  • Serra, Eduard|||0000-0003-2895-9857
  • Lázaro García, Conxi|||0000-0002-7198-5906
Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive soft-tissue sarcomas with a poor survival rate, presenting either sporadically or in the context of neurofibromatosis type 1 (NF1). The histological diagnosis of MPNSTs can be challenging, with different tumors exhibiting great histological and marker expression overlap. This heterogeneity could be partly responsible for the observed disparity in treatment response due to the inherent diversity of the preclinical models used. For several years, our group has been generating a large patient-derived orthotopic xenograft (PDOX) MPNST platform for identifying new precision medicine treatments. Herein, we describe the expansion of this platform using six primary tumors clinically diagnosed as MPNSTs, from which we obtained six additional PDOX mouse models and three cell lines, thus generating three pairs of in vitro-in vivo models. We extensively characterized these tumors and derived preclinical models, including genomic, epigenomic, and histological analyses. Tumors were reclassified after these analyses: three remained as MPNSTs (two being classic MPNSTs), one was a melanoma, another was a neurotrophic tyrosine receptor kinase (NTRK)-rearranged spindle cell neoplasm, and, finally, the last was an unclassifiable tumor bearing neurofibromin-2 (NF2) inactivation, a neuroblastoma RAS viral oncogene homolog (NRAS) oncogenic mutation, and a SWI/SNF-related matrix-associated actin-dependent regulator of chromatin (SMARCA4) heterozygous truncated variant. New cell lines and PDOXs faithfully recapitulated histology, marker expression, and genomic characteristics of the primary tumors. The diversity in tumor identity and their specific associated genomic alterations impacted treatment responses obtained when we used the new cell lines for testing compounds against known altered pathways in MPNSTs. In summary, we present here an extension of our MPNST precision medicine platform, with new PDOXs and cell lines, including tumor entities confounded as MPNSTs in a real clinical scenario. This platform may constitute a useful tool for obtaining correct preclinical information to guide MPNST clinical trials.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas

  • Mazuelas, Helena
  • Magallon-Lorenz, Miriam|||0000-0003-2741-4572
  • Uriarte-Arrazola, Itziar
  • Negro, Alejando
  • Rosas, Inma|||0000-0003-4238-0227
  • Blanco Guillermo, Ignacio|||0000-0002-7414-7481
  • Castellanos, Elisabeth|||0000-0002-8133-5325
  • Lázaro García, Conxi|||0000-0002-7198-5906
  • Gel, Bernat|||0000-0001-8878-349X
  • Carrió, Meritxell|||0000-0002-1258-6593
  • Serra, Eduard|||0000-0003-2895-9857
Cutaneous neurofibromas (cNFs) are benign Schwann cell (SC) tumors arising from subepidermal glia. Individuals with neurofibromatosis type 1 (NF1) may develop thousands of cNFs, which greatly affect their quality of life. cNF growth is driven by the proliferation of NF1 SCs and their interaction with the NF1 microenvironment. We analyzed the crosstalk between human cNF-derived SCs and fibroblasts (FBs), identifying an expression signature specific to the SC-FB interaction. We validated the secretion of proteins involved in immune cell migration, suggesting a role of SC-FB crosstalk in immune cell recruitment. The signature also captured components of developmental signaling pathways, including the cAMP elevator G protein-coupled receptor 68 (GPR68). Activation of Gpr68 by ogerin in combination with the MEK inhibitor (MEKi) selumetinib reduced viability and induced differentiation and death of human cNF-derived primary SCs, a result corroborated using an induced pluripotent stem cell-derived 3D neurofibromasphere model. Similar results were obtained using other Gpr68 activators or cAMP analogs/adenylyl cyclase activators in combination with selumetinib. Interestingly, whereas primary SC cultures restarted their proliferation after treatment with selumetinib alone was stopped, the combination of ogerin-selumetinib elicited a permanent halt on SC expansion that persisted after drug removal. These results indicate that unbalancing the Ras and cAMP pathways by combining MEKi and cAMP elevators could be used as a potential treatment for cNFs.